How to Apply for and Secure EU Funding for Collaborative IBD Research Projects.

[en] The European Union offers opportunities for high-level of funding of collaborative European research. Calls are regularly published: after the end of the FP7 funding programme the new round of Horizon 2020 calls started in 2015. Several topics are relevant to inflammatory bowel disease (IBD) challenges, including chronic disease management, biomarker discovery and new treatments developments. The aim of this Viewpoint article is to describe the new Horizon 2020 instrument and the project submission procedures, and to highlight these through the description of tips and tricks, taking advantage of four examples of successful projects in the field of IBD: the SADEL, IBD-BIOM, IBD Character and BIOCYCLE projects.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Satsangi, Jack

Kitten, Olivier

CHAVEZ, Viviana ; Centre Hospitalier Universitaire de Liège - CHU > Centre d'oncologie

Kalla, Rahul

Prel, Nadege

Meuwis, Marie-Alice ; Université de Liège > Département de chimie (sciences) > Laboratoire de spectrométrie de masse (L.S.M.)

Scott, Stephanie

Bonetti, Illaria

Ventham, Nicholas T.

Louis, Edouard ; Université de Liège > Département des sciences cliniques > Hépato-gastroentérologie

Language :

English

Title :

How to Apply for and Secure EU Funding for Collaborative IBD Research Projects.

Publication date :

2016

Journal title :

Journal of Crohn's and Colitis

ISSN :

1873-9946

eISSN :

1876-4479

Publisher :

Elsevier, United Kingdom

Volume :

Issue :

Pages :

363-70

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://ecco-jcc.oxfordjournals.org/

Commentary :

Available on ORBi :

since 27 January 2017

Statistics

Number of views

80 (5 by ULiège)

Number of downloads

151 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

European Commission. Horizon 2020. The New EU Framework Programme for Research and Innovation. http://ec.europa.eu/research/horizon2020/pdf/press/horizon2020-presentation.pdf.
European Commission. Horizon 2020, Brussels, November 21, 2013. The EU's new research and innovation programme. http://europa.eu/rapid/press-release_MEMO-13-1034_en.htm.
European Commission. Horizon 2020, Funding opportunities, societal challenges. Call: personalized medicine. http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/index.html.
European Commission - Fact Sheet. Horizon 2020: New Work Programme Supports Europe's Growth, Jobs and Competitiveness. Brussels, October 13, 2015. http://europa.eu/rapid/press-release_MEMO-15-5832_en.htm.
European Commission. Health Programme. http://ec.europa.eu/health/programme/policy/index_en.htm.
European Commission. CHAFEA Consumers, Health, Agriculture and Food Executive Agency. http://ec.europa.eu/chafea/.
Innovative Medicines Initiative. The Innovative Medicines Initiative. http://www.imi.europa.eu/.
European Federation of Pharmaceutical Industries and Associations. http://www.efpia.eu/.
Retrieved from The Innovative Medicines Initiative. http://www.imi.europa.eu/.
European Commission. Participant Portal. http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/index.html.
Fit For Health. TUTORIAL. Proposal Preparation, Submission & Evaluation: http://www.fitforhealth.eu/sites/default/files/tutorial_-_proposal_preparation_submission_evaluation.pdf.
European Commission. Guidance for Evaluators of Horizon 2020 Proposals, Brussels, September 26, 2014. http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/pse/h2020-evaluation-faq_en.pdf.
Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res 2011;39:e102.
Lundberg M, Thorsen SB, Assarsson E, et al. Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material. Mol Cell Proteomics 2011;10:M110.004978.
Casén C, Vebø HC, Sekelja M, Hegge FT, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther 2015;42:71-83.
Klla R, Kennedy N, Hjelm F, et al. Proximity Extension Assay technology identifies novel serum biomarkers for predicting inflammatory bowel disease: IBD Character Consortium. J Crohns Colitis 2015;9 Suppl 1:S146-7.
Theodoratou E, Campbell H, Ventham NT, et al. The role of glycosylation in IBD. Nat Rev Gastroenterol Hepatol 2014;11:588-600.
Trbojević Akmačić I, Ventham NT, Theodoratou E, et al. Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. Inflamm Bowel Dis 2015;21:1237-47.
Ventham NT, Kennedy NA, Nimmo ER, Satsangi J. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology 2013;145:293-308.
Ventham NT, Gardner RA, Kennedy NA, et al. Changes to serum sample tube and processing methodology does not cause inter individual variation in automated whole serum N-glycan profiling in health and disease. PLoS One 2015;10:e0123028.
European Commission. Horizon 2020 Statistics. https://ec.europa.eu/programmes/horizon2020/sites/horizon2020/files/horizon_2020_first_results.pdf.